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Abstract
Background: Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH) consists of congenital aplasia of the
uterus and the upper part of vagina due to anomalous development of Müllerian ducts, either isolated or
associated with other congenital malformations, including renal, skeletal, hearing and heart defects. This
disorder has an incidence of approximately 1 in 4500 newborn girls and the aetiology is poorly understood.
Methods and Results: we report on two patients affected by MRKH syndrome in which array-CGH
analysis disclosed an identical deletion spanning 1.5 Mb of genomic DNA at chromosome 17q12. One
patient was affected by complete absence of uterus and vagina, with bilaterally normal ovaries, while the
other displayed agenesis of the upper part of vagina, right unicornuate uterus, non cavitating rudimentary
left horn and bilaterally multicystic kidneys. The deletion encompassed two candidate genes, TCF2 and
LHX1. Mutational screening of these genes in a selected group of 20 MRKH females without 17q12
deletion was negative.
Conclusion: Deletion 17q12 is a rare albeit recurrent anomaly mediated by segmental duplications,
previously reported in subjects with developmental kidney abnormalities and diabetes. The present two
patients expand the clinical spectrum associated with this imbalance and suggest that this region is a
candidate locus for a subset of MRKH syndrome individuals, with or without renal defects.
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Introduction
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome
(MIM 277000) affects about 1 in 4500 female births, pre-
senting with congenital aplasia of the uterus and the
upper part of vagina, in association with unremarkable
development of secondary sexual characteristics and nor-
mal 46, XX karyotype. This disorder can be isolated (type
I; OMIM 277000) and comprises the so-called CAUV
(Congenital Absence of the Uterus and Vagina) and MA
(Müllerian Aplasia), or associated with renal, skeletal
and/or hearing defects. Cardiac and digital anomalies are
rare. Patients with associated anomalies are classified as
MURCS association (MÜllerian duct aplasia, Renal Dys-
plasia and Cervical Somite anomalies), also indicated as
MRKH type II syndrome (OMIM 601076), or GRES (Gen-
ital Renal Ear Syndrome)(OMIM 267400) if the middle
ear is also affected [1]. The most common coexisting
defects affect the upper urinary tract, including unilateral
renal agenesis, ectopia of one or both kidneys, renal hypo-
plasia, horseshoe kidney and hydronephrosis [2]. As thor-
oughly reviewed in a recent paper [1], several inheritance
models have been suggested to explain MRKH syndrome
aetiology, including polygenic/multifactorial causes and
non-genetic issues. Among non-genetic causes maternal
diabetes and the teratogen action of thalidomide-like sub-
stances have been proposed. All the hypotheses are likely
reliable, suggesting that MRKH has a wide aetiological
heterogeneity [1]. The increasing number of familial
cases, the pattern of congenital malformations, the co-
occurrence of Müllerian aplasia in either recessive and
dominant syndromes and the association with chromo-
some rearrangements (see [3] for a review) indicate that
MRKH is a disorder occurring during embryogenesis, the
genetic factors playing a crucial role. So far, WNT4 gene
mutations have shown to be responsible for a clinically
distinct subtype of this disorder, presenting with Mülleri-
an aplasia and hyperandrogenism, with or without renal
aplasia [4].
We report two patients affected by MRKH syndrome
resulting from deletion of the same 1.5 Mb segment at
17q12 band, including TCF2 and LHX1 genes.
Patients
The two patients with Müllerian aplasia reported in this
study were enrolled during a multicentric study of MRKH
syndrome. Twenty additional females with a clinical diag-
nosis of MRHK syndrome without 17q12 chromosome
deletion were investigated for TCF2 and LHX1 gene muta-
tions. All participants were informed about the study and
signed a consent form approved by the Ethical Committee
of each Institute involved.
Patient 1
This patient was the second child of healthy, non consan-
guineous parents. The mother was 28 and the father 33
year-old at conception. Family history was unremarkable.
Pregnancy was normal and delivery at term by caesarian
section, because of maternal indication. Birth weight was
3,250 g (50th centile), length 48 cm (10th centile), and
Apgar scores were 9 and 10 at 1 and 5 minutes. Growth
and psychomotor development were normal, but the girl
experienced several episodes of acute cystitis during
infancy.
She was referred for a genetic opinion at age of 20 years
with a diagnosis of primary amenorrhoea and abnormal
genitalia. Weight was 52 kg (25-50th centile), height 163
cm (50th centile), and OFC 54 cm (25-50th centile). She
had mild dysmorphic features, including laterally sparse
eyebrows, down slanted palpebral fissures, hypertricosis
of upper lip (Figure 1A). A transrectal sonogram showed
congenital absence of the uterus, polycystic left ovary 29 ×
12 × 31 mm, and a likely left müllerian remnant 16 × 18
mm. The right ovary measured 40 × 39 × 45 mm with a
functional cyst of 36 × 38 × 44 mm. A pelvic magnetic res-
onance imaging disclosed normal kidneys, an unusually
thin bladder wall, congenital absence of uterus and
vagina, bilaterally normal ovaries. Audiogram, ECG, car-
diac sonogram and blood glucose level were unremarka-
ble. Standard karyotype was normal (46, XX). At age of 20
years the proband underwent a surgical corrective proce-
dure, with the construction of a neo-vagina. Laparoscopic
exploration confirmed uterine agenesis, normal ovaries
and persisting Müllerian structures. No additional anom-
aly or congenital defects were associated with the genital
malformation.
Patient 2
This patient was the first child of healthy non consanguin-
eous parents. At birth, the father and mother were 30 and
29 year-old respectively. A younger sister was normal.
Family history was negative for renal, genital or skeletal
defects. Pregnancy was unremarkable until the 7th month,
when US scan disclosed bilateral foetal renal cysts. Chro-
mosome analysis on amniocytes was normal (46, XX).
The baby was born at term by caesarean section for obstet-
ric reasons. Birth weight was 3,530 g (50th centile) and
length 51 cm (75th centile).
The patient came to our observation for the first time at
the age of 10 months for evaluation of renal cysts and
then revaluated periodically in the subsequent years.
Renal ultrasound at age of 5 years showed bilaterally
small-sized multicystic kidneys. Both kidneys had diffuse
parenchymal hyperecogenicity, poor cortico-medullary
differentiation, and small subcapsular cysts. The collect-
ing system was not dilated and urinary bladder wall wasOrphanet Journal of Rare Diseases 2009, 4:25 http://www.ojrd.com/content/4/1/25
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regular. These changes were confirmed in subsequent
ultrasounds. The developmental milestones and psycho-
motor development were normal. At the age of 12 years,
menarche was complicated by haematocolpos due to
agenesis of the upper and middle thirds of vagina, which
were surgically corrected. Laparoscopy demonstrated
Müllerian malformations with right unicornuate uterus,
no cavitating rudimentary left horn, right hematosalpinx
and surgically corrected agenesis of the upper and middle
thirds of vagina. Ophtalmologic examination, ECG, 24
hour holter measurement, renal function test, liver func-
tion test, parathyroid hormone measurement, blood glu-
cose level, uric acid level, blood protein level, 24 hour
proteinuria and oxaluria were unremarkable.
At age of 15 years weight was 62.5 Kg (75-90th centile),
height 168 cm (75-90th centile), and OFC 55.8 cm (50-
98th centile).
Methods
Array-CGH
Genomic oligonucleotide-array (244 K; Agilent Technolo-
gies Inc., Palo Alto, CA) was used according to standard
protocol with some modifications. For each patient
genomic DNA was extracted from 2 ml of an EDTA blood
sample. Patients' DNA and a female reference DNA
(Promega, Madison, WI) were Alu I and Rsa I double-
digested (Promega) and purified using DNA Clean and
Concentrator Kit (Zymo Research Corporation; Orange;
CA). Digested DNA was quantified by the fluorimeter
(BioRad, Hercules, CA) and 1 μg of each patient and ref-
erence DNA were labelled with Cy5-dCTP and Cy3-dCTP
(Agilent Technologies Inc.). The Cy5 and Cy3 labelled
DNAs were combined and cleaned-up using Micron YM-
30 columns (Millipore, Bedford, MA). After the addition
of blocking agents and the hybridisation buffer (Agilent
Technologies, Palo Alto, CA), DNAs were denaturated at
95°C and hybridised at 65°C for 40 hours with rotation.
After washes, dried slides were immediately scanned on
the Agilent scanner, imaged with Feature Extraction soft-
ware (v8.5.3) and analysed using the DNA analytics soft-
ware (v4.0) (Agilent Technologies Inc.).
A chromosome 17 custom-microarray was designed in sil-
ico  using the web Agilent eArray database version 4.5
https://earray.chem.agilent.com/earray, in order to test
other MRKH patients for the 17q12 deletion and to even-
tually compare the size of the rearrangements. All the Agi-
lent's high-density CGH probes mapping to chromosome
17 were included in the array format 8 × 15 K. The Agilent-
optimized chromosome X probes have been used as con-
trol (March 2006 release).
A) Patient 1: facial appearance showing mild dysmorphisms Figure 1
A) Patient 1: facial appearance showing mild dysmorphisms. B) Detail of array-CGH graphical overview of 17q12 
deletion spanning about 1.5 Mb from A_16_P20635582 (31,897,238 Mb) to A_16_P20639170 (33,322,972 Mb) probes.Orphanet Journal of Rare Diseases 2009, 4:25 http://www.ojrd.com/content/4/1/25
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FISH
Deletions were confirmed by FISH analysis using RP11-
19G24 clone selected from the 32 K genomic library
(BACPAC Resources Center; http://bacpac.chori.org/),
based on mapping data (UCSC; http://genome.ucsc.edu.,
March 2006 release). DNA was extracted by a Quantum
Prep MiniPrep Kit (BioRad, Hercules, CA) and Spectrum-
Green-dUTP or SpectrumOrange-dUTP labeled using the
Nick Translation kit (Vysis Inc., Downers Grove, IL)
according to the manufacturer's protocol. Metaphase
spreads were obtained following standard procedures and
FISH analysis was performed as previously described [5].
Mutational Analysis
To amplify the entire coding sequence and flanking
intronic portions of TCF2 and LHX1, 9 and 5 primer pairs
were designed respectively. The PCR reactions (except
LHX1 exon 2) were performed in a 25 μl volume contain-
ing 1.5 mM MgCl2, 250 μM dNTPs, 1 μM of each primer,
50 ng of genomic DNA and 1.5 U of AmpliTaq Gold DNA
polymerase (Applied Biosystem, Foster City, CA) with an
initial denaturation step of 12 min at 95°C followed by
35 cycles at 94°C, 30 sec; 60°C, 30 sec; 72°C, 30 sec and
a final elongation of 7 min at 72°C. LHX1 exon 2 (high
GC content) has been amplified in a 25 μl volume con-
taining 1 mM MgSO4, 0.6× PCR Enhancer Solution, 250
μM dNTPs, 1 μM of each primer, 50 ng of genomic DNA
and 1.5 U of Platinum Pfx DNA Polymerase (Invitrogen,
Carlsbad, CA). PCR products were purified using ExoSAP-
IT (USB Corporation, Cleveland, OH) and sequenced
directly on an automated sequencer (ABI 3100; Applied
Biosystem) using the ABI-PRISM big-dye Terminator
Cycle Sequencing Ready Reaction kit (Applied Biosys-
tem).
Results
Array-CGH analysis performed on patients 1 and 2 dis-
closed a de novo deletion at 17q12 band (Figure 1B) con-
firmed by FISH using a specific BAC clone. FISH analysis
extended to parents showed a normal hybridization pat-
tern, demonstrating the de novo origin of the rearrange-
ment. In both cases the deletion spanned about 1.5 Mb
from A_16_P20635582 to A_16_P20639170
(31.897.238-33.322.972 Mb) probes (UCSC Genome
Browser; http://genome.ucsc.edu, March 2006 Release),
including16 RefSeq genes, and it was not listed among the
copy number polymorphisms (Database of Genomic Var-
iants; http://projects.tcag.ca/variation/). Subsequently, 20
consecutive patients with a clinical diagnosis of MRKH
syndrome were tested by a focused chromosome 17 array-
CGH analysis in order to assess the prevalence of 17q12
deletion in females affected by MRKH. This analysis was
negative. These 20 patients were investigated also by
direct sequencing of candidate genes mapping to 17q12
(TCF2 and LHX1). Molecular testing disclosed a number
of known polymorphisms, but no pathogenic mutation
(Table 1).
Discussion
An increasing number of familial cases suggest that MRKH
syndrome can be inherited as an autosomal dominant
incompletely penetrant trait, either due to single gene
mutation or chromosomal imbalances [1]. Clinical fea-
tures are consistent with a developmental defect attribut-
able to an initial affection of the intermediate mesoderm
leading to an alteration of the blastema of the cervicotho-
Table 1: Mutational analysis of candidate-genes
Patient ID TCF2 LHX1
RK104
RK105 1654-21 C/T
RK106 841+26 A/G
RK107 841+26 A/G
RK111 1654-21 C/T NO DNA
RK112 1653+48insC; 1654-21 C/T
RK113 1654-21 T/T
RK114 1654-21 C/T
RK115 170+42 G/T
RK116 1654-21 C/T
RK117
RK118 676-34 C/T; 841+26 A/G
RK119 841+26 A/G
RK120 1654-21 C/T
RK121 1653+48insC
RK122 1654-21 T/T
RK123 1654-21 C/T
RK124
RK125 1653+48insC
RK126
List of the known polymorphisms disclosed by the mutational analysis 
of LHX1 and TCF2 genes in 20 selected chromosomally normal MRKH 
females, tested negative for 17q12 deletion.Orphanet Journal of Rare Diseases 2009, 4:25 http://www.ojrd.com/content/4/1/25
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racic somites and the pronephric ducts [6], but develop-
mental genes investigated, such as WT1,  HOXA7,
HOXA13 and PBX1, did not reveal any pathogenic muta-
tion [7,8]. Among chromosome causes, an identical
t(12;14)(q14;q31) detected in two unrelated Indian
females, a maternally inherited terminal deletion of 4q
and 22q11.21 deletion, overlapping the DiGeorge syn-
drome region, have been described in females with syn-
dromic MRKH. However, so far no candidate gene was
identified in the unbalanced regions [9-11].
Array-CGH technique has offered in the last years new
opportunities to discover cryptic chromosome imbal-
ances causative of congenital malformations. This
approach allowed Cheroki et al. to confirm the involve-
ment of 22q region in the MRKH aetiology [12] and to
detect a de novo deletion at 17q12 in one patient present-
ing with absent uterus, severe learning disability and sei-
zures, without diabetes and renal malformations [13]. We
have reported two patients evaluated for Müllerian ducts
aplasia in which array-CGH analysis disclosed an identi-
cal deletion at chromosome 17q12, spanning about 1.5
Mb of genomic DNA. One patient displayed congenital
absence of uterus and vagina, with bilaterally normal ova-
ries without any additional anomaly, while the other had
agenesis of the upper part of vagina, right unicornuate
uterus and non cavitating rudimentary left horn associ-
ated with bilaterally multicystic kidneys. In both patients
psychomotor development was normal. This is a rare
albeit recurrent imbalance detected so far in a few other
subjects investigated using genomic microarray. Mefford
et al. identified the same 1.5 Mb deletion in a foetus pre-
senting with grossly abnormal, dysplastic multicystic kid-
neys and compared this case with five paediatric patients
with renal disease and three subjects affected by isolated
MODY5. It was found that the breakpoints were identical
in all but one case, who displayed a larger deletion, and
occurred at segmental-duplication clusters with multiple
regions of high identity (up to 99%) [14]. The deleted seg-
ment encompassed 16 known genes, including TCF2 and
LHX1. Mutations in TCF2 gene, also known as hepatocyte
nuclear factor-1-beta (HNF1β), which occur in individu-
als affected by maturity-onset diabetes of the young type
5 (MODY5; MIM 137920) and renal manifestations [15],
have been associated with Müllerian disorders [1]. In par-
ticular, two of four affected females in a MODY5 family
segregating TCF2 mutations had Müllerian aplasia [16],
while in another MODY5 family, the proband displayed
cystic kidneys and uterus didelphys and her affected sec-
ond son had renal cysts and hypospadias [17]. TCF2 is
expressed in renal metanephroi at preglomerular stages
during metanephrogenesis [18]. Urinary and genital sys-
tem are embryologically correlated, both originating from
a common mesodermal ridge. Edghill et al. [19] have esti-
mated that about 10% of subjects with TCF2 mutations
also display some genital system anomaly. LHX1 encodes
a transcription factor with a DNA-binding homeodomain
and two cysteine-rich LIM domains that are thought to be
involved in protein-protein interactions [20]. In mouse,
this gene was shown to be involved in genitourinary sys-
tem developmental processes, including Müllerian ducts
[21]. To assess the contribution of these genes to MRKH
syndrome, we performed a mutational analysis of 20 non
deleted MRKH females. Analysis of 40 chromosomes dis-
closed several polymorphic changes, in the absence of any
pathogenic variation.
Conclusion
The recurrent 17q12 deletion is associated with a wide
clinical spectrum which is further expanded by the
patients reported in this study. Indeed, 17q12 deletion
appears to be pathogenetically related with a subset of
individuals affected by MRKH syndrome, with or without
renal disease. The present data also recommend searching
for 17q12 hemizygosity and/or mutations in the candi-
date TCF2 and LHX1 genes, both in type I and type II
MRKH syndrome.
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